Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKG:2196)
15.70
0.00 (0.00%)
Apr 3, 2025, 4:08 PM HKT
HKG:2196 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 40,396 | 40,911 | 43,377 | 38,666 | 29,910 | Upgrade
|
Other Revenue | 671.23 | 488.71 | 574.48 | 345.58 | 396.96 | Upgrade
|
Revenue | 41,067 | 41,400 | 43,952 | 39,011 | 30,307 | Upgrade
|
Revenue Growth (YoY) | -0.80% | -5.81% | 12.66% | 28.72% | 6.02% | Upgrade
|
Cost of Revenue | 21,426 | 21,717 | 23,256 | 20,294 | 13,798 | Upgrade
|
Gross Profit | 19,641 | 19,683 | 20,696 | 18,717 | 16,509 | Upgrade
|
Selling, General & Admin | 12,963 | 14,087 | 12,999 | 12,328 | 11,124 | Upgrade
|
Research & Development | 3,644 | 4,346 | 4,302 | 3,837 | 2,795 | Upgrade
|
Other Operating Expenses | -47.52 | -44.99 | -88.15 | -57.86 | -108.24 | Upgrade
|
Operating Expenses | 16,668 | 18,499 | 17,275 | 16,180 | 13,891 | Upgrade
|
Operating Income | 2,974 | 1,184 | 3,420 | 2,537 | 2,618 | Upgrade
|
Interest Expense | -1,432 | -1,325 | -963.81 | -822.54 | -880.95 | Upgrade
|
Interest & Investment Income | 2,478 | 3,866 | 4,660 | 4,858 | 2,484 | Upgrade
|
Currency Exchange Gain (Loss) | -13.36 | 13.03 | 62.36 | 154.63 | -24.79 | Upgrade
|
Other Non Operating Income (Expenses) | -41.41 | -57.73 | -31.78 | -31.06 | -81.16 | Upgrade
|
EBT Excluding Unusual Items | 3,965 | 3,680 | 7,147 | 6,695 | 4,115 | Upgrade
|
Impairment of Goodwill | - | - | -180 | -150 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -115.94 | -488.66 | -2,498 | -110.19 | 494.8 | Upgrade
|
Gain (Loss) on Sale of Assets | 371.01 | 5.56 | 125.6 | -15.42 | 5.71 | Upgrade
|
Asset Writedown | -57.93 | -42.14 | -20.48 | -171.01 | -10.11 | Upgrade
|
Other Unusual Items | -5.44 | 109.38 | 0.25 | -206.16 | 72.71 | Upgrade
|
Pretax Income | 4,169 | 3,265 | 4,574 | 6,043 | 4,678 | Upgrade
|
Income Tax Expense | 656.84 | 369.5 | 626.92 | 1,066 | 737.86 | Upgrade
|
Earnings From Continuing Operations | 3,512 | 2,895 | 3,947 | 4,976 | 3,940 | Upgrade
|
Minority Interest in Earnings | -742.55 | -508.8 | -216.66 | -247.56 | -277.17 | Upgrade
|
Net Income | 2,770 | 2,386 | 3,731 | 4,729 | 3,663 | Upgrade
|
Preferred Dividends & Other Adjustments | - | 1.05 | - | - | - | Upgrade
|
Net Income to Common | 2,770 | 2,385 | 3,731 | 4,729 | 3,663 | Upgrade
|
Net Income Growth | 16.08% | -36.04% | -21.10% | 29.10% | 10.27% | Upgrade
|
Shares Outstanding (Basic) | 2,670 | 2,670 | 2,607 | 2,563 | 2,563 | Upgrade
|
Shares Outstanding (Diluted) | 2,670 | 2,670 | 2,607 | 2,563 | 2,563 | Upgrade
|
Shares Change (YoY) | 0.02% | 2.40% | 1.74% | - | - | Upgrade
|
EPS (Basic) | 1.04 | 0.89 | 1.43 | 1.85 | 1.43 | Upgrade
|
EPS (Diluted) | 1.04 | 0.89 | 1.43 | 1.85 | 1.43 | Upgrade
|
EPS Growth | 16.10% | -37.52% | -22.50% | 29.10% | 10.27% | Upgrade
|
Free Cash Flow | 66.79 | -1,922 | -1,671 | -1,035 | -1,857 | Upgrade
|
Free Cash Flow Per Share | 0.03 | -0.72 | -0.64 | -0.40 | -0.72 | Upgrade
|
Dividend Per Share | 0.320 | 0.270 | 0.420 | 0.560 | 0.430 | Upgrade
|
Dividend Growth | 18.52% | -35.71% | -25.00% | 30.23% | 10.26% | Upgrade
|
Gross Margin | 47.83% | 47.54% | 47.09% | 47.98% | 54.47% | Upgrade
|
Operating Margin | 7.24% | 2.86% | 7.78% | 6.50% | 8.64% | Upgrade
|
Profit Margin | 6.74% | 5.76% | 8.49% | 12.12% | 12.09% | Upgrade
|
Free Cash Flow Margin | 0.16% | -4.64% | -3.80% | -2.65% | -6.13% | Upgrade
|
EBITDA | 5,514 | 3,883 | 5,541 | 4,184 | 4,083 | Upgrade
|
EBITDA Margin | 13.43% | 9.38% | 12.61% | 10.72% | 13.47% | Upgrade
|
D&A For EBITDA | 2,540 | 2,699 | 2,121 | 1,647 | 1,465 | Upgrade
|
EBIT | 2,974 | 1,184 | 3,420 | 2,537 | 2,618 | Upgrade
|
EBIT Margin | 7.24% | 2.86% | 7.78% | 6.50% | 8.64% | Upgrade
|
Effective Tax Rate | 15.75% | 11.32% | 13.71% | 17.65% | 15.77% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.